NCT05229497 - A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 29, 2024

Conditions

Advanced Malignant Tumors

Interventions

DRUG

AK112

IV infusion,Specified dose on specified days

DRUG

AK117

IV infusion,Specified dose on specified days

DRUG

Carboplatin

IV infusion,Specified dose on specified days

DRUG

Cisplatin

IV infusion,Specified dose on specified days

DRUG

5-Fluorouracil

IV infusion,Specified dose on specified days

Trial Locations (1)

RECRUITING

Zhejiang Cancer Hospital, Hangzhou